Rigel Pharmaceuticals Files 8-K on Financials

TL;DR

Rigel Pharma dropped an 8-K updating its financial condition - check the filings for deets.

AI Summary

Rigel Pharmaceuticals, Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance. No specific financial figures or significant events were detailed in the provided excerpt.

Why It Matters

This filing provides an update on Rigel Pharmaceuticals' financial health and operational results, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting on financial condition and operations, without immediate news of significant positive or negative events.

Key Players & Entities

• RIGEL PHARMACEUTICALS, INC. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• August 6, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock, par value $0.001 per share RIGL The Nasdaq Stock Mar

Filing Documents

• tm2420634d4_8k.htm (8-K) — 25KB
• tm2420634d4_ex99-1.htm (EX-99.1) — 98KB
• 0001104659-24-086271.txt ( ) — 307KB
• rigl-20240806.xsd (EX-101.SCH) — 3KB
• rigl-20240806_lab.xml (EX-101.LAB) — 33KB
• rigl-20240806_pre.xml (EX-101.PRE) — 22KB
• tm2420634d4_8k_htm.xml (XML) — 4KB

02

Item 2.02. Results of Operations and Financial Condition. On August 6, 2024, Rigel Pharmaceuticals, Inc. (" Rigel ") announced certain financial results for its second quarter ended June 30, 2024. A copy of Rigel's press release, titled "Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update," is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Rigel, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release, dated August 6, 2024, titled "Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 6, 2024 RIGEL PHARMACEUTICALS, INC. By: /s/ Ray Furey, J.D. Ray Furey, J.D. Executive Vice President, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR